First-in-Human Orthotopic Transcatheter Tricuspid Valve Replacement in a Patient With a Left Ventricular Assist Device Authors: Connor P Craig, Payton D Kendsersky, Nicolas H Pope, Brian A Houston, Toby B Steinberg, Lucas P Witer, Ryan J Tedford, Daniel H Steinberg, Nicholas S Amoroso Published: 2026 ABSTRACT AbstractBackgroundSignificant tricuspid regurgitation (TR) is common in patients after left ventricular assist device (LVAD) implantation and is associated with an increased risk of mortality. Studies evaluating concomitant surgical tricuspid valve intervention have not consistently demonstrated benefit.First-in-Human SummaryWe describe a first-in-human transcatheter tricuspid valve replacement (TTVR) using the Evoque system in a 46-year-old man with medically refractory, severe TR and right ventricular failure after LVAD implantation.DiscussionOur case demonstrates that TTVR is a technically feasible treatment option for LVAD patients with refractory TR, in this case improving symptoms and reducing the need for chronic inotropic support.NoveltyTo our knowledge, this is the first report of TTVR using the Evoque valve system in a patient with an LVAD.Take-Home MessagesPatients with severe TR after LVAD implantation have worse outcomes, but surgical tricuspid valve intervention at the time of LVAD implantation has not consistently shown benefit. TTVR platforms may represent a therapeutic alternative for patients with persistent symptomatic TR.Key words: Evoque, LVAD, refractory TR, TTVR Tricuspid regurgitation (TR) is a relatively common phenomenon in patients who undergo left ventricular assist device (LVAD) implantation, as approximately 12% have severe postoperative TR.1 Left ventricular unloading can reduce pulmonary pressures and right ventricular (RV) afterload, sometimes improving TR. Alternatively, RV function and size can adversely change after LVAD implantation, resulting in new or worsening functional TR.2 Patients with significant postoperative moderate to severe TR have an increased risk of mortality and, when there is coexisting RV failure, that risk is even higher.3 Despite this, studies that have evaluated tricuspid valve surgery for TR at the time of LVAD implantation have had conflicting results, with more contemporary data demonstrating no clear short- or long-term benefit.4,5 TTVR for patients with more than moderate postoperative TR with or without RV failure after LVAD implantation may play a meaningful role in reducing long-term morbidity and mortality. We report to our knowledge the first-in-human TTVR using the Evoque tricuspid valve replacement system (Edwards Lifesciences) for a post-LVAD patient with refractory TR and RV failure. Take-Home Messages •Patients with severe tricuspid regurgitation after LVAD implantation have worse outcomes; however, studies evaluating surgical valve repair or replacement at the time of LVAD implantation have shown mixed results, with major barriers likely being increased procedural complexity and duration. Patients with severe tricuspid regurgitation after LVAD implantation have worse outcomes; however, studies evaluating surgical valve repair or replacement at the time of LVAD implantation have shown mixed results, with major barriers likely being increased procedural complexity and duration. •The use of TTVR platforms may represent a feasible therapeutic alternative for patients with persistent valvular dysfunction and symptoms after LVAD implantation. The use of TTVR platforms may represent a feasible therapeutic alternative for patients with persistent valvular dysfunction and symptoms after LVAD implantation. Case Summary Presentation and medical history Our patient was a 46-year-old man with nonischemic cardiomyopathy who had undergone implantation of a HeartMate 3 LVAD in August 2024. Additional relevant medical history included ventricular tachycardia and complete heart block managed with cardiac resynchronization therapy with implantable cardioverter-defibrillator (ICD). His postoperative course was complicated by RV failure resulting in RV enlargement and worsening TR. He had recurrent hospital admissions for worsening renal function and right-sided heart failure with persistent NYHA functional class IV symptoms despite pump speed adjustments, ultimately requiring chronic dobutamine infusion. He was evaluated for orthotopic heart transplantation but was deemed ineligible owing to substance use, frailty, and patient preference. Reoperation for surgical tricuspid valve repair was deemed high risk by the surgical team. The patient was subsequently referred for transcatheter tricuspid valve intervention in February 2025. Given the large 12-mm tricuspid valve coaptation gap and presence of an RV defibrillator lead, the estimation by the heart team was that tricuspid transcatheter edge-to-edge repair (t-TEER) would result in suboptimal reduction of TR. The patient's risk profile for TTVR was considered favorable given the tricuspid valve anatomy, a preserved RV–pulmonary artery coupling ratio, and pre-existing indication for indefinite anticoagulation. Finally, despite a lack of head-to-head comparison, current data indicated a higher likelihood of meaningful TR reduction with TTVR compared with t-TEER; it was proposed that maximizing TR reduction to increase right-to-left transit and LVAD flows could be most predictably accomplished with TTVR.6,7 In consult with the heart team, jailing the patient's RV defibrillator lead was estimated to be lower clinical risk than extraction and reimplantation after TTVR. The patient was thus considered for TTVR with an Evoque valve, in consultation with the advanced heart failure, electrophysiology, cardiac surgery, anesthesiology, and interventional cardiology teams. Investigations Pre- and postprocedural transthoracic echocardiography (TTE) was obtained. The preprocedural TTE was notable for severe TR (effective regurgitant orifice area: 0.67 cm2, regurgitant volume: 40 mL) with mildly reduced RV systolic function (tricuspid annular plane systolic excursion: 15 mm, RV fractional area of change: 38%). The RV–pulmonary artery coupling ratio was 0.51. Transesophageal echocardiography (TEE) performed 1 month preprocedure demonstrated a 12-mm coaptation gap, minimal shadowing of relevant structures from the LVAD hardware, and a tricuspid valve annulus of 4.7 cm. The predominant mechanism of TR appeared to be secondary due to annular dilation, with mild interaction of the defibrillator lead. Contrast-enhanced chest/abdomen/pelvis/cardiac computed tomography using a dedicated TTVR protocol was obtained. Results were notable for tricuspid annular dimensions of 41.4 × 46.7 mm with an area of 15.4 cm2 and average diameter of 45.9 mm (an anticipated annular device oversizing of 6.7%-7.4%). The RV was severely dilated. The patient's iliofemoral venous anatomy was suitable for large-bore femoral access. There was no inferior vena cava–to-valve offset, low inferior vena cava–to-annulus distance of 46 mm, and favorable right atrial/ventricular depth of 160 mm. Management The patient was admitted and underwent medical optimization with aggressive diuresis using intravenous furosemide over a 12-day period before his procedure. The procedure was performed in April 2025 under general anesthesia with continuous TEE. Right internal jugular vein access was obtained with a 7-F sheath, and a right heart catheterization was performed (Table 1). Primary access was then obtained in the right femoral vein with an 8-F sheath. Contralateral arterial and venous access were obtained with 5-F and 10-F sheaths, respectively. A percutaneous suture device was deployed at all femoral access sites using a “preclose” technique. An intracardiac echocardiography catheter was advanced into the right atrium for adjunct imaging, anticipating potential TEE image shadowing over the right heart from the LVAD components. A 0.035-inch guidewire with preformed ventricular curl was advanced from the primary venous access site to the superior vena cava. Full heparinization was initiated to maintain an activated clotting time of >250 seconds throughout the course of the procedure. Table 1Preprocedural and Postprocedural Patient HemodynamicsPreprocedurePostprocedure 1Postprocedure 2LVAD speed (rpm)5,7005,4005,700Dobutamine rate (μg/kg/min)555RA pressure (mm Hg)12 (v-waves: 24)66RV pressure (mm Hg)24/1022/732/10PA pressure (mm Hg)22/12/1524/5/1426/6/16PCWP (mm Hg)5910CO/CI, thermodilution (L/min, L/min/m2)2.90/1.673.27/1.893.30/1.91CO/CI, Fick (L/min, L/min/m2)5.45/3.156.46/3.737.50/4.30PAPi23.173.33CI = cardiac index; CO = cardiac output; LVAD = left ventricular assist device; PA = pulmonary artery; PAPi = pulmonary artery pulsatility index; PCWP = pulmonary capillary wedge pressure; RA = right atrium; RV = right ventricle. Preprocedural and Postprocedural Patient Hemodynamics CI = cardiac index; CO = cardiac output; LVAD = left ventricular assist device; PA = pulmonary artery; PAPi = pulmonary artery pulsatility index; PCWP = pulmonary capillary wedge pressure; RA = right atrium; RV = right ventricle. The primary venous access sheath was exchanged for an articulating introducer advanced to the right atrium. The guidewire was advanced under echocardiographic and fluoroscopic guidance into position in the apical RV. The articulating sheath was then withdrawn. The right femoral vein was then dilated, and the Evoque steerable valve delivery system with a 52-mm Evoque valve was introduced via the femoral vein to the right atrium, over the wire, and into the RV. The delivery system was positioned to be coaxial with the tricuspid annulus, and leaflet capture was confirmed on both TEE and intracardiac echocardiography. Ventricular expansion followed by atrial expansion of the device was performed during a brief reduction in LVAD speed from 5,700 to 5,400 rpm. There was no significant hemodynamic perturbation during deployment. The delivery system was withdrawn from the body along the wire. At the end of the procedure, there was no regurgitation of the bioprosthetic valve and trivial paravalvular leak at the site of the preexisting jailed ICD lead. The transvalvular mean gradient on TEE was 1 mm Hg. The access site suture devices were then tightened with adjunct manual compression applied for hemostasis. Protamine was administered. There were no procedural complications. Postprocedural hemodynamics was notable for improved right arterial pressure, cardiac output, and pulmonary artery pulsatility index (Table 1), without additional LVAD speed changes. Similarly, postprocedural TTE confirmed reduction in TR severity from severe to trace (Video 1). Two months after TTVR, the patient's chronic dobutamine was discontinued given improved symptoms and clinical status. At the 6-month follow-up, he had no recurrent hospitalizations. End-organ function demonstrated improvement, with a creatinine level of 1.5 mg/dL (decreased from a peak of 5.7 mg/dL) and normalization of his aspartate aminotransferase and alanine aminotransferase. B-type natriuretic peptide level remained <500 pg/mL. His daily torsemide dosing was reduced from 100 to 50 mg. With improvement in his renal function, he was successfully transitioned from isosorbide dinitrate and hydralazine to losartan. He returned to work and participated in regular exercise, with NYHA functional class II symptoms. Routine interrogation of his ICD revealed stable sensing and pacing, without arrhythmia. Novelty of the Submission To our knowledge, this is the first reported experience of TTVR using the Evoque valve system in a patient with an LVAD and an RV defibrillator lead. Prior case reports exist in the literature for TTVR using transcatheter edge-to-edge repair and bicaval systems in patients with LVADs. Andreas et al8 reported t-TEER in a 59-year-old patient who had undergone HeartMate 3 LVAD implantation and tricuspid valve repair with an annuloplasty ring, with recurrent severe TR treated with a MitraClip XTR device as a bridge to transplantation. Staubach et al9 recently described a 72-year-old man with a HeartMate 3 and torrential TR who underwent successful t-TEER using 2 Pascal devices in the anteroseptal position, with only minimal TR on follow-up TEE. Finally, Chandran et al10 reported the implantation of a TricValve transcatheter bicaval valve system in an 80-year-old woman with a HeartMate II LVAD with NYHA functional class IV symptoms and persistent low-flow alarms. First-in-Human Evoque TTVR in a Patient With a Left Ventricular Assist Device Graphic representation demonstrating (A) pre-TTVR and (B) post-TTVR anatomy. (C) Condensed Table 1 showing preprocedural and postprocedural hemodynamics. Intraprocedural fluoroscopy (D) during and (E) after implant. TTE parasternal right ventricular inflow view demonstrating TR jet on color flow (F) preprocedure and (G) postprocedure. Intraprocedural TEE demonstrating TR on color flow (H) preprocedure and (I) postprocedure. CI = cardiac index; CO = cardiac output; HM3 = HeartMate 3; LVAD = left ventricular assist device; PA = pulmonary artery; PAPi = pulmonary artery pulsatility index; PCWP = pulmonary capillary wedge pressure; RA = right atrium; RV = right ventricle; TR = tricuspid regurgitation; TTE = transthoracic echocardiography; TTVR = transcatheter tricuspid valve replacement. Future Directions Post-LVAD TTVR may represent a reasonable alternative to concomitant surgical tricuspid valve intervention at the time of LVAD implantation. There are several theoretical advantages to this approach, including the ability to assess response of TR to left ventricular unloading after implantation and reducing operative time and complexity, while improving patient quality of life and potentially morbidity and mortality in appropriately selected patients. More work needs to be done to determine which patient factors best predict a response to this therapy. Additionally, longitudinal follow-up of larger cohorts could help characterize the degree of benefit, if any, in this population. Conclusions Our case demonstrates the first-in-human use of the transcatheter Evoque tricuspid valve replacement system for the management of severe TR and right heart failure after LVAD implantation. TTVR may be a feasible option for LVAD patients with new or worsening postoperative TR and RV dysfunction. Funding Support and Author Disclosures Dr Tedford has reported consulting relationships with and honoraria/consulting fees from Abbott, Acorai, Adona, Aria CV Inc, Boston Scientific, CVRx, Endotronix, Edwards Lifesciences, Fauna Bio, Gradient, Imbria, Medtronic, Merck, Miter, Morphic Therapeutics, Pulmovant, Restore Medical, Tempus AI, 35Pharma, and United Therapeutics; and serving on the steering committee for Abbott, Edwards, Endotronix, Gradient, Merck, Restore Medical, and Tempus AI as well as research advisory board for Abiomed. Dr Amoroso has reported consulting relationships with and honoraria/consulting fees in the past 24 months from Abbott, Boston Scientific, Edwards Lifesciences, Egnite, JenaValve, and VDyne; serving on the advisory board for Boston Scientific, Egnite, Nininger Medical, and VDyne; and having a stock-options interest in Nininger Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. Appendix For a supplemental video, please see the online version of this paper. Appendix Video 1 Preprocedural and Postprocedural Tricuspid Regurgitation Demonstrated on TTE (Left) Preprocedural and (Right) postprocedural tricuspid regurgitation on TTE right ventricular inflow view. References Associated Data Supplementary Materials Video 1 Preprocedural and Postprocedural Tricuspid Regurgitation Demonstrated on TTE (Left) Preprocedural and (Right) postprocedural tricuspid regurgitation on TTE right ventricular inflow view.